home / stock / eton / eton articles
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call p...
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmac...
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (NASDAQ:ETON), an innovative pharmaceutical company focused on dev...
News, Short Squeeze, Breakout and More Instantly...
Eton Pharmaceutcials Inc. Company Name:
ETON Stock Symbol:
NASDAQ Market:
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call p...
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call point Transaction is expected to be accretive to 2024 earnings Estimated peak sales of more than $10 million annually U.S. phenylketonuria ("PKU"...
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growth Full year 2023 revenues reached $31.6 million with product sales and royalty revenues of $26.1 million, a 132% increase from 2022 Announce...